The Role of the Bile Microbiome in Common Bile Duct Stone Development.
16S rRNA gene sequencing
CBD stone
Enterococcaceae
Enterococcus
metabolites
microbiome
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
27 Jul 2023
27 Jul 2023
Historique:
received:
18
06
2023
revised:
20
07
2023
accepted:
24
07
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Common bile duct (CBD) stones are a health concern for 10-20% of individuals with symptomatic gallstones, leading to health complications and placing a burden on healthcare systems. This study was initiated to investigate the changes in microbiome compositions and the metabolic signature associated with CBD stones. The research approach integrated taxonomic and functional data with metabolomics data, complemented by in vivo experiments. In a single tertiary healthcare institution, a total of 25 patients were enrolled who had undergone endoscopic retrograde cholangiopancreatography (ERCP) between February 2019 and January 2021. We harvested DNA from bile samples acquired from these individuals. The amplification of the bacterial 16S rRNA gene V3-V4 region was conducted through polymerase chain reaction (PCR), followed by sequencing. We utilized QIIME2 for a comprehensive data analysis. Furthermore, we performed a metabolomic analysis of the bile samples using nuclear magnetic resonance (NMR) spectroscopy. For the assessment of functional gene enrichment, we employed MetaboAnalyst 5.0. Lastly, we executed in vivo experiments on C57BL/6 mice and undertook histological examinations of tissue samples. Out of the 25 study subjects, 17 underwent ERCP due to CBD stones (the CBD stone group), while the remaining 8 had the procedure for different reasons (the non-CBD stone group). An alpha diversity analysis showed a significantly greater microbial diversity in the bile samples of the non-CBD stone group ( Our study highlights the importance of biliary dysbiosis and bile metabolites, specifically acetate and formate, in CBD stone development and progression. These findings have implications for the development of diagnostic and therapeutic strategies using microbiomes for CBD stones.
Identifiants
pubmed: 37626621
pii: biomedicines11082124
doi: 10.3390/biomedicines11082124
pmc: PMC10452286
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : INHA UNIVERSITY HOSPITAL Research Grant
ID : N/A
Références
World J Surg Oncol. 2020 Jan 24;18(1):19
pubmed: 31980025
BMC Gastroenterol. 2020 Mar 6;20(1):59
pubmed: 32143645
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Tech Vasc Interv Radiol. 2015 Dec;18(4):244-55
pubmed: 26615165
PLoS One. 2016 Mar 01;11(3):e0150519
pubmed: 26930491
Arch Surg. 1996 Apr;131(4):389-94
pubmed: 8615724
Gut. 2017 May;66(5):765-782
pubmed: 28122906
Curr Opin Gastroenterol. 2014 May;30(3):332-8
pubmed: 24625896
Life (Basel). 2022 Oct 03;12(10):
pubmed: 36294975
Mucosal Immunol. 2019 Jul;12(4):851-861
pubmed: 30952999
Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1193-1205
pubmed: 30791792
Immunity. 2019 Sep 17;51(3):443-450.e4
pubmed: 31422870
Mol Metab. 2020 Mar;33:23-37
pubmed: 31402327
Appl Environ Microbiol. 2001 Dec;67(12):5482-7
pubmed: 11722896
Science. 2018 May 25;360(6391):
pubmed: 29798856
Ann Surg. 1966 Jul;164(1):90-100
pubmed: 5329901
Exp Mol Med. 2019 Jul 23;51(7):1-13
pubmed: 31337751
Gut. 2021 Jul;70(7):1287-1298
pubmed: 33811041
Trends Immunol. 2016 Jul;37(7):462-476
pubmed: 27216414
Anticancer Res. 2021 Jan;41(1):327-334
pubmed: 33419827
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Synth Syst Biotechnol. 2021 Nov 24;6(4):414-428
pubmed: 34901480
Microorganisms. 2020 Jun 02;8(6):
pubmed: 32498344
PLoS One. 2013 Jul 29;8(7):e70657
pubmed: 23923015
Sci Rep. 2019 Nov 1;9(1):15844
pubmed: 31676822
J Korean Med Sci. 2021 Apr 19;36(15):e94
pubmed: 33876584
Front Cell Infect Microbiol. 2021 Nov 23;11:751795
pubmed: 34888258